All That Investors Need To Know About Bellamy’s Australia 1HFY19 Results

Bellamy’s Australia

On 27th February 2019, Bellamy’s Australia Limited (ASX: BAL), which is in the business of manufacturing organic milk and food products for infants, announced its 1HFY19 results. The company reported revenue of $129.64 million in 1HFY19, down by 25.9% from the previously reported revenue of $174.91 million in 1HFY18. Some of the reasons for the declining revenue were the decision to run-down trade inventory prior to the Australia-label rebrand, an observed slowdown in overall category performance.

EBITDA for 1HFY19 also took a hit and reported at $13.98 million which is down by massive 59.9% from $34.85 million, reported in 1HFY18. EBIT decreased by 65.7% from $32.72 million in 1HFY18 to $11.2 million in 1HFY19.  [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

Net profit after tax (NPAT) also took a hit and nosedived from $22.4 million in 1HFY18 to $8.13 million in 1HFY19, a massive decline of 63.7%. This has led to a subsequent decline in the earnings per share (EPS) as well. The basic EPS for the 1HFY18 was stated around 21.5 cents per share which reduced to 7.2 cents per share after the decline in the NPAT. Diluted EPS saw an equivalent fall as well and fell from 20.4 cents per share in 1HFY18 to 6.8 cents per share in 1HFY19.

Cash flow from operating activities has reduced significantly from $59.1 million in 1HFY18 to $8.58 million in 1HFY19. This reduction is primarily due to reduced cash receipts from customers (from $166.86 million in 1HFY18 to $124.67 million in 1HFY19) and increase in cash payments to suppliers and employees (from $98.49 million in 1HFY18 to $108.84 million in 1HFY19).

On the balance sheet, the net cash has gone up to $94.8 million in 1HFY19 compared to $87.6 million reported at the end of 2HFY18. The cash conversion has also been improved due to Cyclical phasing of creditor payment cycles and Structural changes in the supply chain as a result of direct sourcing strategy. This efficiency in the cash conversion cycle has reduced the inventory from $90.45 million to $61.03 million in the same period which has resulted in the decline in total assets from $280.81 million in 2HFY18 to $262.04 million at the end of 1HFY19. On the liabilities side, the company has maintained its long term zero debt levels. There is an increase in the short-term provisions from $45 million in 2HFY18 to $58 million in 1HFY19, but the total liabilities have decreased significantly from $73.45 million to $43.99 million in the same period.

The company did not declare any dividend amid 67% fall in profits. However, the outlook given by the company was full of confidence. It is expecting the SAMR to guide up the group revenue after the loss of already delayed registration which was seen evident in the 1HFY19 numbers. The total revenue of the group is expected to touch $275 million – $300 million in FY19.

Amid mixed numbers, the stock price closed almost flat (up by 0.25%) on ASX at A$8.09 as on 27th February 2019. The YTD return of the stock is 6.32%.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report